Key takeaways
Epclusa (sofosbuvir/velpatasvir) and Technivie (ombitasvir/paritaprevir/ritonavir) are both antiviral medications used to treat hepatitis C, but they have some key differences. Epclusa is a combination of two antiviral medications and is FDA-approved to treat all six types of chronic hepatitis C in both adults and children. It is taken as one tablet once a day, with or without food. Technivie, on the other hand, was specifically used for type 4 hepatitis C and required combination with ribavirin. It was taken as two tablets in the morning with a meal. Technivie has been discontinued and is no longer available, while Epclusa remains in use. Epclusa can cause mild side effects like headache and fatigue, and it interacts with many medications, including those for heartburn. Technivie was discontinued due to newer medications like Epclusa that do not require ribavirin, which can have many side effects.
